Transaction Overview - The company has approved the acquisition of 51% equity in Changsha Kexin Tumor Hospital Co., Ltd. for a total amount of RMB 357 million [1] - The valuation for the equity transfer was based on an asset evaluation report from Shanghai Dongzhou Asset Appraisal Co., Ltd. [1] Progress Update - All parties involved have confirmed the completion of pre-delivery obligations as per the equity transfer agreement [2] - The company has made the initial payment for the equity transfer to Hunan Kexin Health Industry Group Co., Ltd. [2] - The equity transfer has been officially registered, and the business license for Changsha Kexin has been updated [2] Changes in Business Registration - After the completion of the business registration change, the company now holds 51% of Changsha Kexin, making it a subsidiary included in the company's consolidated financial statements [2] - The updated shareholding structure shows the company holding 51% and Kexin Group holding 49% [2]

盈康生命科技股份有限公司 关于收购长沙珂信肿瘤医院有限公司51%股权 证券代码：300143 证券简称：盈康生命 公告编号：2025-025 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开第 六届董事会第十六次会议、第六届监事会第十四次会议，审议通过了《关于收购长 沙珂信肿瘤医院有限公司 51%股权的议案》，同意公司收购长沙珂信肿瘤医院有 限公司（以下简称"长沙珂信"）51%股权（以下合称"本次交易"）。本次交易 股权转让的价格以上海东洲资产评估有限公司出具的《盈康生命科技股份有限公 司拟收购长沙珂信肿瘤医院有限公司部分股权所涉及的长沙珂信肿瘤医院有限公 司股东全部权益价值资产评估报告》（东洲评报字[2025]第 0058 号）为定价参考 依据，经交易各方协商确定，本次交易总金额为人民币 35,700 万元。具体内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于收购长沙珂信肿瘤医院有 限公司 51%股权的公告》（公告编号：20 ...

Financial Performance - In Q1 2025, the company achieved a revenue of 409.037 million yuan, maintaining stability [3] - Net profit attributable to shareholders was 29.993 million yuan, a year-on-year increase of 14.4% [3] - Net profit excluding non-recurring items was 29.965 million yuan, up 25.8% year-on-year [3] Business Strategy - The company focuses on the integration of traditional medical services with AI technology to enhance operational efficiency and service quality [6] - The healthcare service revenue accounted for 76.47% of total income in 2024 [6] - The company is transitioning from a traditional medical group to a technology-driven health management provider [6] Mergers and Acquisitions - The company plans to continue acquisitions, targeting profitable hospitals with a minimum of 400 beds for general hospitals or 300 beds for specialty hospitals [4] - The acquisition of Changsha Kexin is expected to enhance business scale and profitability, particularly in oncology services [8] AI Integration - The company is implementing a comprehensive AI strategy across its operations, focusing on improving diagnostic capabilities, patient experience, and operational management [4] - AI applications are structured in three layers: data infrastructure, capability components, and intelligent interaction engines [4] Operational Efficiency - In 2024, the company achieved a revenue per employee of 710,000 yuan, an increase of 8.9% year-on-year [5] - Profit per employee reached 52,600 yuan, reflecting a year-on-year growth of 20.2% [5] Care Services Development - The company is expanding its nursing and elderly care services, leveraging its existing facilities in Shanghai [3] - Plans include enhancing home care services and integrating traditional and modern medical practices [3]

证券代码：300143 证券简称：盈康生命 公告编号：2025-024 盈康生命科技股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，盈康生命科技股份有限公司（以下简称 "公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net）；或关注微信公众号（名称:全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00—17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 盈康生命科技股份有限公司董事会 二〇二五年四月三十日 1 ...

Core Viewpoint - 盈康生命科技股份有限公司 continues to demonstrate steady growth in 2024, driven by its differentiated and AI-enabled strategies, enhancing operational efficiency and profitability [2][3]. Financial Performance - In Q1 2025, the company achieved revenue of 409 million yuan, a year-on-year decrease of 1.73%; net profit attributable to shareholders was 30 million yuan, an increase of 14.4%; and non-recurring net profit was also 30 million yuan, up 25.77% [2]. - For the full year 2024, the company reported revenue of 1.559 billion yuan, a year-on-year increase of 6.01%, and a net profit of 115 million yuan, up 14.92% [2]. - The compound annual growth rates for revenue and net profit over the past five years were 23.9% and 14.9%, respectively, indicating a trend of high-quality development [2]. AI Empowerment and Innovation - Since 2021, the company has strategically positioned itself in the "medical + AI" sector, establishing itself as a pioneer in group AI deployment within the industry [3]. - The company embraces a "three-full" concept of AI, focusing on full participation, full coverage, and full process, to enhance diagnostic capabilities, patient experience, and operational management [3]. - In 2024, the company reported an 8.9% increase in revenue per capita and a 20.2% increase in profit per capita, while the period expense ratio decreased by 0.8 percentage points [3]. Differentiated Development Path - The company has driven business growth through a differentiated approach, with the medical services segment generating revenue of 1.19 billion yuan in 2024, of which tumor-related revenue was 380 million yuan, accounting for 31.9% of medical service revenue, an increase of 17% year-on-year [4]. - The company has developed a "three-special" system focusing on specialized departments, diseases, and expertise, integrating medical innovation to enhance user experience and meet diverse needs [4]. External Growth Strategy - In 2025, the company plans to deepen its tumor medical specialty through external growth, announcing a cash acquisition of 51% of Changsha Kexin Tumor Hospital for 357 million yuan [6]. - Changsha Kexin, established in 2015, is a tertiary tumor specialty hospital with 420 beds and advanced radiotherapy equipment, performing over 8,000 minimally invasive surgeries annually [6]. - The acquisition is part of the company's strategy to enhance its regional medical center layout and is expected to significantly improve its technical depth and service breadth in the tumor specialty field, thereby strengthening its profitability [6].

Core Viewpoint - Yingkang Life reported a slight decline in revenue but a significant increase in net profit, showcasing strong profitability and growth potential in a challenging private hospital industry [1][2][4] Financial Performance - Revenue for Q1 2025 decreased by 1.73% year-on-year to 409 million yuan, while net profit attributable to shareholders increased by 14.4% to 29.993 million yuan [1] - Non-recurring net profit surged by 25.8% year-on-year to 29.965 million yuan, indicating improved profit quality [2] Operational Efficiency - The company achieved a reduction in operating expenses, with the expense ratio decreasing by 2.9 percentage points [2] - The oncology revenue share rose to 31.9%, up 17 percentage points from the previous year, becoming a key growth driver [2] Strategic Initiatives - Yingkang Life announced the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, aiming to enhance its regional medical center layout and expand oncology treatment capabilities [2] - The company has implemented an "AI + Medical" strategy since 2021, integrating AI across all aspects of diagnosis, management, and service [3] Technological Advancements - The launch of the "AI Innovation Application Platform" in April 2023, in collaboration with industry leaders, aims to enhance the entire service chain from disease screening to health management [3] - The company is transitioning from "tool empowerment" to "ecosystem reconstruction" in AI healthcare, providing a replicable model for intelligent transformation in the industry [3] Industry Positioning - Yingkang Life stands out in the private hospital sector, successfully navigating cost pressures and achieving profit growth while many smaller private hospitals face losses [3][4] - The company is positioned as a benchmark for transformation in the private hospital industry, leveraging AI, specialization, and external expansion to enhance quality alongside scale [4]

证券代码：300143 证券简称：盈康生命 公告编号：2025-023 盈康生命科技股份有限公司 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》 《公司章程》及有关法律、法规的规定。 二、监事会会议审议情况 （一）审议通过《关于公司2025年第一季度报告的议案》 第六届监事会第十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于2025年4月25日以电话、 邮件方式向全体监事发出召开公司第六届监事会第十五次（临时）会议的通知。 本次会议于2025年4月28日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会 议室以现场的方式召开。会议应出席监事3人，实际出席监事3人，监事龚雯雯、 王旭东、李超峰以现场方式出席会议并投票表决。本次会议由监事会主席龚雯雯 女士主持，公司部分高级管理人员列席了会议。 公司监事会根据《中华人民共和国公司法》和《公司章程》的有关规定，本 着对全体股东负责的态度，谨慎履行法律、法规赋予的职责，审核了公司《2025 年第一季度报告》 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-022 盈康生命科技股份有限公司 第六届董事会第十七次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第十七次（临时）会议的通知。会 议于 2025 年 4 月 28 日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会议室 以现场结合通讯的方式召开。会议应出席董事 7 人，实际出席董事 7 人，董事谭丽 霞、彭文以现场方式出席会议并投票表决，董事潘绵顺、沈旭东、独立董事杜媛、独 立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本次会议由董事长谭 丽霞女士主持，公司的监事、高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公司 章程》及有关法律、法规的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第一季度报告的议案》 董事会审议了公司《2025 年第一 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥409,036,863.19, a decrease of 1.73% compared to ¥416,230,884.39 in the same period last year[4] - Net profit attributable to shareholders increased by 14.36% to ¥29,992,667.09 from ¥26,225,857.82 year-on-year[10] - The net profit after deducting non-recurring gains and losses rose by 25.77% to ¥29,965,266.34 compared to ¥23,824,607.82 in the previous year[10] - Basic and diluted earnings per share were both ¥0.0404, a decline of 1.46% from ¥0.0410 in the previous year due to an increase in the number of shares outstanding[10] - Total operating revenue for the current period is CNY 409,036,863.19, a decrease of 1.3% from CNY 416,230,884.39 in the previous period[21] - Net profit for the current period reached CNY 29,086,075.84, an increase of 11.6% compared to CNY 26,057,158.43 in the previous period[22] - Operating profit increased to CNY 38,345,193.85, compared to CNY 34,701,575.17 in the previous period, reflecting a growth of 15.1%[22] - Total comprehensive income attributable to the parent company was CNY 29,989,909.88, compared to CNY 26,236,853.28 in the previous period, indicating an increase of 10.6%[22] Cash Flow and Assets - Cash flow from operating activities decreased by 32.86% to ¥68,679,664.08, down from ¥102,289,209.00 in the same period last year[10] - The company's cash and cash equivalents decreased to CNY 1,138,969,420.06 from CNY 1,240,041,262.14, a decline of about 8.2%[18] - The company reported a decrease in cash and cash equivalents at the end of the period to CNY 1,124,401,835.39 from CNY 519,518,553.40 in the previous period[26] - The total assets increased to CNY 3,546,266,054.50 from CNY 3,536,733,888.57, a growth of approximately 0.3%[19] - Total liabilities decreased to CNY 1,036,423,148.83 from CNY 1,058,411,535.22, a reduction of about 2.1%[19] - The company's net loss decreased to CNY -1,368,078,948.71 from CNY -1,398,071,615.80, indicating an improvement in financial performance[20] - Long-term borrowings increased to CNY 180,500,000.00 from CNY 152,601,666.67, reflecting a growth of approximately 18.3%[19] - The total equity increased to CNY 2,509,842,905.67 from CNY 2,478,322,353.35, a rise of about 1.3%[20] Shareholder Information - The company has a total of 17,573 common shareholders as of the end of the reporting period[12] - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[12] - The company reported a total of 263,884,885 shares held by Qingdao Yinkang Medical Investment Co., Ltd., representing a significant portion of the unrestricted circulating shares[13] - The top ten unrestricted shareholders collectively hold a substantial number of shares, with the largest individual shareholder holding 1.47%[13] - As of March 31, 2025, the company has repurchased 6,156,752 shares, accounting for 0.82% of the total share capital[13] - The company has not reported any changes in the participation of major shareholders in margin trading activities[14] - There are no significant changes in the status of preferred shareholders or restricted shares[14] Acquisition and Investments - The company acquired 51% equity in Changsha Kexin Tumor Hospital for a total amount of RMB 357 million[14] - The acquisition aims to strengthen the company's presence in the oncology service sector and enhance its operational capabilities[15] - The funding for the acquisition will come from the company's own funds and self-raised funds[15] - After the transaction, Changsha Kexin will become a subsidiary and will be included in the company's consolidated financial statements[15] - The transaction was approved by the company's board and supervisory board, and does not require shareholder approval[15] Operating Costs and Revenue - Total operating costs decreased to CNY 365,010,030.67 from CNY 382,865,011.79, reflecting a reduction of approximately 4.7%[21] - Total revenue from operating activities was CNY 401,154,630.61, down 4.2% from CNY 418,030,793.48 in the previous period[25] - Cash flow from investing activities resulted in a net outflow of CNY 170,839,764.41, worsening from a net outflow of CNY 73,896,713.14 in the previous period[26] - The company incurred credit impairment losses of CNY -6,803,765.69, compared to CNY -3,026,574.95 in the previous period, indicating a significant increase in losses[22]

北京市金杜（青岛）律师事务所 关于盈康生命科技股份有限公司 2024 年年度股东大会之 法律意见书 致：盈康生命科技股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受盈康生命科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国 境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政 区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章、 规范性文件和现行有效的《盈康生命科技股份有限公司章程》（以下简称《公司 章程》）的有关规定，指派律师出席了公司于 2025 年 4 月 18 日召开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关事项出具本 法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 29 日刊登于巨潮资讯网及深圳证券交易所 ...